Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Adoptive T cell therapy (ACT) has yielded high response rates in melanoma, however 50–60% of patients experience no clinical benefit. Here, the authors identify predictive biomarkers, high non-synonymous mutation and high expressed neoantigen load, that associate with clinical benefit in ACT melanom...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martin Lauss, Marco Donia, Katja Harbst, Rikke Andersen, Shamik Mitra, Frida Rosengren, Maryem Salim, Johan Vallon-Christersson, Therese Törngren, Anders Kvist, Markus Ringnér, Inge Marie Svane, Göran Jönsson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/63635278846d435eabbeb4ee5d2c1d15
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63635278846d435eabbeb4ee5d2c1d15
record_format	dspace
spelling	oai:doaj.org-article:63635278846d435eabbeb4ee5d2c1d152021-12-02T17:06:26ZMutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma10.1038/s41467-017-01460-02041-1723https://doaj.org/article/63635278846d435eabbeb4ee5d2c1d152017-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-017-01460-0https://doaj.org/toc/2041-1723Adoptive T cell therapy (ACT) has yielded high response rates in melanoma, however 50–60% of patients experience no clinical benefit. Here, the authors identify predictive biomarkers, high non-synonymous mutation and high expressed neoantigen load, that associate with clinical benefit in ACT melanoma patients.Martin LaussMarco DoniaKatja HarbstRikke AndersenShamik MitraFrida RosengrenMaryem SalimJohan Vallon-ChristerssonTherese TörngrenAnders KvistMarkus RingnérInge Marie SvaneGöran JönssonNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Martin Lauss Marco Donia Katja Harbst Rikke Andersen Shamik Mitra Frida Rosengren Maryem Salim Johan Vallon-Christersson Therese Törngren Anders Kvist Markus Ringnér Inge Marie Svane Göran Jönsson Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
description	Adoptive T cell therapy (ACT) has yielded high response rates in melanoma, however 50–60% of patients experience no clinical benefit. Here, the authors identify predictive biomarkers, high non-synonymous mutation and high expressed neoantigen load, that associate with clinical benefit in ACT melanoma patients.
format	article
author	Martin Lauss Marco Donia Katja Harbst Rikke Andersen Shamik Mitra Frida Rosengren Maryem Salim Johan Vallon-Christersson Therese Törngren Anders Kvist Markus Ringnér Inge Marie Svane Göran Jönsson
author_facet	Martin Lauss Marco Donia Katja Harbst Rikke Andersen Shamik Mitra Frida Rosengren Maryem Salim Johan Vallon-Christersson Therese Törngren Anders Kvist Markus Ringnér Inge Marie Svane Göran Jönsson
author_sort	Martin Lauss
title	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
title_short	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
title_full	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
title_fullStr	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
title_full_unstemmed	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
title_sort	mutational and putative neoantigen load predict clinical benefit of adoptive t cell therapy in melanoma
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/63635278846d435eabbeb4ee5d2c1d15
work_keys_str_mv	AT martinlauss mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT marcodonia mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT katjaharbst mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT rikkeandersen mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT shamikmitra mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT fridarosengren mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT maryemsalim mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT johanvallonchristersson mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT theresetorngren mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT anderskvist mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT markusringner mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT ingemariesvane mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma AT goranjonsson mutationalandputativeneoantigenloadpredictclinicalbenefitofadoptivetcelltherapyinmelanoma
_version_	1718381614839365632

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Ejemplares similares